Jorey Chernett Acquires 450,000 Shares of Neuronetics (NASDAQ:STIM) Stock

Neuronetics, Inc. (NASDAQ:STIM) major shareholder Jorey Chernett acquired 450,000 shares of the company’s stock in a transaction that occurred on Thursday, March 19th. The stock was acquired at an average price of $1.33 per share, with a total value of $598,500.00. Following the acquisition, the insider directly owned 8,573,804 shares of the company’s stock, valued at approximately $11,403,159.32. This represents a 5.54% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Wednesday, March 18th, Jorey Chernett bought 607,400 shares of Neuronetics stock. The shares were acquired at an average price of $1.35 per share, for a total transaction of $819,990.00.
• On Tuesday, March 17th, Jorey Chernett purchased 531,000 shares of Neuronetics stock. The stock was acquired at an average cost of $1.16 per share, with a total value of $615,960.00.

Neuronetics Stock Performance

NASDAQ:STIM opened at $1.45 on Friday. The company has a fifty day simple moving average of $1.60 and a two-hundred day simple moving average of $2.02. The company has a market cap of $100.46 million, a price-to-earnings ratio of -2.46 and a beta of 0.87. The company has a quick ratio of 2.09, a current ratio of 2.02 and a debt-to-equity ratio of 2.51. Neuronetics, Inc. has a 52 week low of $0.80 and a 52 week high of $5.05.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. The business had revenue of $41.78 million for the quarter, compared to analysts’ expectations of $40.84 million. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%. As a group, equities analysts anticipate that Neuronetics, Inc. will post -1.13 earnings per share for the current fiscal year.

Neuronetics News Summary

Here are the key news stories impacting Neuronetics this week:

• Positive Sentiment: Major insider buying: Jorey Chernett (a major shareholder) increased his stake with multiple purchases over March 17–19 totaling roughly 1.59M shares across filings, boosting ownership and signaling insider confidence. SEC Form 4 filing Investing.com coverage
• Positive Sentiment: Q4 results modestly beat expectations: EPS of ($0.10) vs. (~$0.12) est. and revenue $41.8M vs. $40.8M expected — a near‑term operational positive but the company remains unprofitable. Earnings call transcript
• Neutral Sentiment: Mixed analyst and institutional profile: MarketBeat notes one Buy and one Sell rating, a consensus “Hold,” active institutional turnover, and wide variance in targets — underlines divergent views and liquidity sensitivity for this small‑cap stock. MarketBeat coverage
• Negative Sentiment: Price‑target reduction from Canaccord: Canaccord cut its target from $7 to $3 (still a Buy), narrowing perceived upside and likely weighing on sentiment despite the maintained rating. Benzinga report
• Negative Sentiment: Short‑term sell pressure / headline reaction: AAII and other outlets highlighted a multi‑percent intraday decline (around 5%), attributing it to the mix of analyst action, profit‑taking after recent moves, and the company’s continued negative margins and leverage. AAII article

Analyst Upgrades and Downgrades

STIM has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Neuronetics in a research note on Thursday, January 22nd. Wall Street Zen lowered shares of Neuronetics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Canaccord Genuity Group reduced their target price on shares of Neuronetics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $3.00.

Institutional Trading of Neuronetics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Madryn Asset Management LP purchased a new stake in Neuronetics during the 4th quarter worth about $25,497,000. UBS Group AG increased its holdings in shares of Neuronetics by 580.7% in the 3rd quarter. UBS Group AG now owns 2,164,831 shares of the company’s stock valued at $5,910,000 after acquiring an additional 1,846,801 shares during the last quarter. Lane Generational LLC acquired a new stake in shares of Neuronetics during the 4th quarter worth about $2,353,000. Goldman Sachs Group Inc. lifted its stake in Neuronetics by 2,993.3% during the first quarter. Goldman Sachs Group Inc. now owns 630,393 shares of the company’s stock worth $2,320,000 after purchasing an additional 610,014 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Neuronetics by 172.3% during the second quarter. Geode Capital Management LLC now owns 879,045 shares of the company’s stock worth $3,068,000 after purchasing an additional 556,268 shares during the last quarter. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.